Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fimasartan + hydrochlorothiazide
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fimasartan + hydrochlorothiazide is an oral fixed-dose combination of two antihypertensive agents: fimasartan, a non-peptide angiotensin II receptor antagonist (ARB), and hydrochlorothiazide, a thiazide diuretic. Fimasartan selectively blocks the angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone-mediated sodium and water retention, thereby lowering blood pressure. Hydrochlorothiazide acts on the distal renal tubules to inhibit sodium reabsorption, promoting diuresis and further reducing blood volume. The combination is primarily indicated for the treatment of essential hypertension in patients who do not achieve adequate blood pressure control with monotherapy. Developed by Boryung Pharmaceutical (also known as Boryung Pharmaceuticals), this combination has demonstrated superior efficacy in lowering both systolic and diastolic blood pressure compared to fimasartan alone, with a comparable safety profile[2][4][5][6][8].
- Brand names
- Kanarb plusDiarakhor
- Other names
- fimasartan + hydrochlorothiazide
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)
Beyond the preview
Go deeper on fimasartan + hydrochlorothiazide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fimasartan + hydrochlorothiazide.